{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T01:18:35Z","timestamp":1711761515852},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,29]]},"DOI":"10.7759\/cureus.57165","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T09:05:34Z","timestamp":1711703134000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-D Alloimmunization Following Rhesus-Incompatible Platelet Transfusion in a Myelodysplastic Syndrome Patient"],"prefix":"10.7759","author":[{"given":"Rahimie","family":"Hanafi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razan Hayati","family":"Zulkeflee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Nazri","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Ilyia Syazwani","family":"Saidin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumaiyah","family":"Adzahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosline","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0085-4","article-title":"Myelodysplastic syndromes current treatment algorithm 2018","volume":"8","author":"Steensma DP","year":"2018","unstructured":"Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018, 8:47. 10.1038\/s41408-018-0085-4","journal-title":"Blood Cancer J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12091","article-title":"BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn","volume":"24","author":"Qureshi H","year":"2014","unstructured":"Qureshi H, Massey E, Kirwan D, et al.. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med. 2014, 24:8-20. 10.1111\/tme.12091","journal-title":"Transfus Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13158","article-title":"Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study","volume":"168","author":"Cid J","year":"2015","unstructured":"Cid J, Lozano M, Ziman A, et al.. Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study. Br J Haematol. 2015, 168:598-603. 10.1111\/bjh.13158","journal-title":"Br J Haematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1519","article-title":"Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology","volume":"19","author":"Schiffer CA","year":"2001","unstructured":"Schiffer CA, Anderson KC, Bennett CL, et al.. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001, 19:1519-38. 10.1200\/JCO.2001.19.5.1519","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2021.04.006","article-title":"Red-cell alloimmunization profile in multi transfused patients: findings and insights of a blood transfusion service","volume":"28","author":"Pereira Bueno ML","year":"2021","unstructured":"Pereira Bueno ML, Mitestainer MB, Da Silva JA, Benites BD, Roversi FM. Red-cell alloimmunization profile in multi transfused patients: findings and insights of a blood transfusion service. Transfus Clin Biol. 2021, 28:258-63. 10.1016\/j.tracli.2021.04.006","journal-title":"Transfus Clin Biol"},{"key":"ref6","article-title":"Blood groups and red cell antigens","author":"Dean L","year":"2005","unstructured":"Dean L. Blood groups and red cell antigens. National Center for Biotechnology Information, Bethesda, USA; 2005."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijpo.2021.060","article-title":"Anti-D alloimmunization after platelet transfusion","volume":"8","author":"Shah RJ","year":"2021","unstructured":"Shah RJ. Anti-D alloimmunization after platelet transfusion. Indian J Pathol Oncol. 2021, 8:306-8. 10.18231\/j.ijpo.2021.060","journal-title":"Indian J Pathol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2009.03.023","article-title":"RBC alloimmunization is an important complication of FFP transfusion: a case report of immune anti-D induced by apheresis fresh frozen plasma","volume":"16","author":"Liu F","year":"2009","unstructured":"Liu F, Zhou FY, Hu LH. RBC alloimmunization is an important complication of FFP transfusion: a case report of immune anti-D induced by apheresis fresh frozen plasma. Transfus Clin Biol. 2009, 16:400-3. 10.1016\/j.tracli.2009.03.023","journal-title":"Transfus Clin Biol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.08.009","article-title":"Non-RhD (anti-E) red cell alloimmunization following platelet transfusion: a case report and implications on quality of the platelet concentrates and antibody screening protocols","volume":"44","author":"Subramaniyan R","year":"2022","unstructured":"Subramaniyan R. Non-RhD (anti-E) red cell alloimmunization following platelet transfusion: a case report and implications on quality of the platelet concentrates and antibody screening protocols. Hematol Transfus Cell Ther. 2022, 44:272-4. 10.1016\/j.htct.2020.08.009","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000351230","article-title":"Platelet transfusion - the art and science of compromise","volume":"40","author":"Cid J","year":"2013","unstructured":"Cid J, Harm SK, Yazer MH. Platelet transfusion - the art and science of compromise. Transfus Med Hemother. 2013, 40:160-71. 10.1159\/000351230","journal-title":"Transfus Med Hemother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12899","article-title":"Mitigation strategies for anti-D alloimmunization by platelet transfusion in haematopoietic stem cell transplant patients: a survey of NCCN(\u00ae) centres","volume":"115","author":"Poston JN","year":"2020","unstructured":"Poston JN, Sugalski J, Gernsheimer TB, Marc Stewart F, Pagano MB. Mitigation strategies for anti-D alloimmunization by platelet transfusion in haematopoietic stem cell transplant patients: a survey of NCCN(\u00ae) centres. Vox Sang. 2020, 115:334-8. 10.1111\/vox.12899","journal-title":"Vox Sang"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/224497-anti-d-alloimmunization-following-rhesus-incompatible-platelet-transfusion-in-a-myelodysplastic-syndrome-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T09:05:38Z","timestamp":1711703138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/224497-anti-d-alloimmunization-following-rhesus-incompatible-platelet-transfusion-in-a-myelodysplastic-syndrome-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.57165","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}